Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China

doi:10.12998/wjcc.v8.i13.2778

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5305)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

218

WORD

122

HTML

2570

Figures (1-1)

222

Tables (1-2)

253

Sum=3385

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

663

Download

1257

Sum=1920

Jul 6, 2020 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jul 6, 2020; 8(13): 2778-2786
Published online Jul 6, 2020. doi: 10.12998/wjcc.v8.i13.2778

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan–Meier analysis of overall survival and disease-free survival according to treatment group. A: Kaplan–Meier analysis of overall survival according to treatment group; B: Kaplan–Meier analysis of disease-free survival according to treatment group. AG: Nab-paclitaxel plus gemcitabine; GEM: Gemcitabine.

Citation: Yin ZZ, Zhao ZM, Tang WB, Jiang N, Zhang KD, Song YY, Wang Y, Li CG, Gao YX, Liu R. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. World J Clin Cases 2020; 8(13): 2778-2786
URL: https://www.wjgnet.com/2307-8960/full/v8/i13/2778.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i13.2778